Where does Cadila Healthcare Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cadila Healthcare Ltd. ranks #4,456 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cadila Healthcare Ltd. hold?

Cadila Healthcare Ltd. holds 79 US utility patents granted between 2015 and 2022, spanning 18 technology areas.

What is Cadila Healthcare Ltd.'s Innovation Score?

Cadila Healthcare Ltd. has an Innovation Score of 40.6 out of 100 (top 35% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cadila Healthcare Ltd. focus on?

Cadila Healthcare Ltd.'s top technology area is C07D (Heterocyclic Compounds) with 46 patents, ranking #177 of 3,165 assignees active in that subclass. Grants appear in 18 CPC subclasses total.

Is Cadila Healthcare Ltd.'s patent grant rate increasing or decreasing?

Cadila Healthcare Ltd.'s recent grant velocity is -82% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Cadila Healthcare Ltd.'s patents?

Cadila Healthcare Ltd.'s patents average 14.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cadila Healthcare Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cadila Healthcare Ltd.

USPTO PatentsView assignee record - 79 granted patents across 18 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cadila ranks #4,456 of 49,997 tracked US assignees by granted-patent volume, with 79 patents across 18 technology areas.

#4,456
of 49,997 US assignees by volume: Top 35%
by Innovation Score (40.6/100): 14.3
avg claims per patent: -82%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4456 · Foreign Corporation #4,456 · 79 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 79 grants
TOP-DECILE #4,456/49,997
PHOTO-FINISH Biocatch
CPC-FOCUS C07D · 18 areas
INNOV-PAR 40.6/100
CLAIMS-RICH 14.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -82% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Biocatch Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cadila’s 40.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 15.1 pts (37%) Velocity 1.9 pts (5%) Breadth 15.0 pts (37%) Claim depth 8.6 pts (21%)

Qualcomm Incorporated · highest

85
Airex · near

41
Cadila Healthcare · this assignee

41
OBI Pharma · near

41
Oscor · near

41
Selecta Biosciences · near

41
3D Lighting… · lowest

7

What this shows Cadila's Innovation Score is 40.6/100 (top 35% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cadila?

Each dot is one of Cadila’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cadila’s own 14.3 claims/patent is ABOVE the 14.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cadila vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cadila's grants concentrate

Cadila Healthcare Ltd. is a focused PatentsView assignee: 18 CPC subclasses with 58.2% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (21 grants) versus a trough of 3 in 2020. By volume, Cadila sits between Biocatch Ltd. and ECA Medical Instruments.

Cadila's three-year grant acceleration

Cadila Healthcare Ltd. shows 4 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Biocatch

79
Bioventures

79
Checkpoint Systems

79
Csem Centre Suiss…

79
Corning Precision…

79
Createme

79
Early Morning

79
ECA Medical Instr…

79
Cadila Healthcare ◀

79

What this shows Cadila holds 79 patents at rank #4,458, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cadila

By rank, the assignees closest to #4,458 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Cadila's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Cadila, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Cadila ranks #177 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (41 here).

Selecta Biosciences, Inc. 41 OBI Pharma, Inc. 41 Oscor Inc. 41 Airex Co., Ltd. 41

Similar claim depth

Nearest assignees by average claims per patent (14.3 here).

UNIVERSITÉ Paris-sud 14.3 avg Element Six Technologies Limited 14.3 avg Saint Louis University 14.3 avg Invacare Corporation 14.3 avg

Cadila's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 35% higher than 65% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Cadila Healthcare Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	15	19.0%
2016	15	19.0%
2017	21	26.6%
2018	10	12.7%
2019	6	7.6%
2020	3	3.8%
2021	5	6.3%
2022	4	5.1%

Which technologies does Cadila Healthcare Ltd. patent most?

C07D - Heterocyclic Compounds 46

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 45

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 44

C07C - Acyclic OR Carbocyclic Compounds 10

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 9

Y10T - Technical Subjects Covered BY Former US Classification 8

C07K - Peptides 7

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

B65B - Machines, Apparatus OR Devices FOR, OR Methods OF, Packaging Articles OR MATERIALS; Unpacking 4

C30B - Single-crystal Growth ; Unidirectional Solidification OF Eutectic Material OR Unidirectional Demixing OF Eutectoid MATERIAL; Refining BY Zone-melting OF Material ; Production OF A Homogeneous Polycrystalline Material With Defined Structure ; Single Crystals OR Homogeneous Polycrystalline Material WI 4

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 4

Y02A - Technologies FOR Adaptation TO Climate Change 2

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

Top 15 of 18 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cadila Healthcare Ltd.'s patent record in context - here's where to go next.

Cadila Healthcare Ltd.'s lead technology class is C07D (Heterocyclic Compounds), 58.2% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #4,456 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cadila Healthcare Ltd. against Biocatch Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.